Fig. 2From: Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxelForest plot showing hazard ratios for progression-free survival. The forest plots indicate the hazard ratios (HRs) and 95% confidence intervals (CIs) according to each factor. Evaluation of factors contributing to the prolongation of progression-free survival (PFS) with baseline clinical factors, stratified with absolute lymphocyte counts (ALC) ≥1500/μLBack to article page